Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Merck KGaA to Build $326 Million Bioprocessing Production Center in Korea

publication date: Mar 21, 2024

Germany’s Merck together with MilliporeSigma, its US-Canada life science division, announced plans to invest $326 million in a new Bioprocessing Production Center in Daejeon, South Korea. The company said the new facility will be its largest investment in Asia-Pacific life science infrastructure so far. The new facility will offer a full range of services for biologic drugs, including process development, clinical research and commercial manufacturing, for in-demand biologic products. Merck, which expects to hire about 300 employees to staff the facility, said the new facility reflects Asia-Pacific’s growing importance in biologic drugs. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital